1. Home
  2. KOS vs NTLA Comparison

KOS vs NTLA Comparison

Compare KOS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

N/A

Current Price

$2.15

Market Cap

1.7B

Sector

Energy

ML Signal

N/A

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

N/A

Current Price

$11.48

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KOS
NTLA
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2011
2016

Fundamental Metrics

Financial Performance
Metric
KOS
NTLA
Price
$2.15
$11.48
Analyst Decision
Hold
Buy
Analyst Count
13
20
Target Price
$3.12
★ $22.78
AVG Volume (30 Days)
★ 15.9M
4.2M
Earning Date
11-02-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.43
EPS
★ N/A
N/A
Revenue
★ $1,288,352,000.00
$67,671,000.00
Revenue This Year
$39.59
N/A
Revenue Next Year
N/A
$229.31
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 16.92
52 Week Low
$0.84
$7.95
52 Week High
$3.34
$18.48

Technical Indicators

Market Signals
Indicator
KOS
NTLA
Relative Strength Index (RSI) 35.21 46.64
Support Level $1.92 $11.26
Resistance Level $3.08 $13.59
Average True Range (ATR) 0.17 0.87
MACD -0.07 -0.06
Stochastic Oscillator 17.86 25.60

Price Performance

Historical Comparison
KOS
NTLA

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: